NASDAQ:BJDX

Bluejay Diagnostics - BJDX Stock Forecast, Price & News

$0.75

+0.01 (+1.90%)

(As of 11/25/2022 08:57 PM ET)

Add

Compare

Today's Range: $0.63
▼
$0.75
50-Day Range: $0.63
▼
$0.89
52-Week Range: $0.61
▼
$3.59

Volume: 26,600 shs
Average Volume: 545,220 shs
Market Capitalization: $15.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Bluejay Diagnostics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,233.7% Upside
$10.00 Price Target
Short Interest: Healthy
1.54% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.29) to ($0.05) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

138th out of 1,044 stocks

Surgical & Medical Instruments Industry

14th out of 104 stocks

3.5

Analyst's Opinion

Consensus Rating
Bluejay Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Bluejay Diagnostics has a forecasted upside of 1,233.7% from its current price of $0.75.
Amount of Analyst Coverage
Bluejay Diagnostics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.54% of the float of Bluejay Diagnostics has been sold short.
Short Interest Ratio / Days to Cover
Bluejay Diagnostics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bluejay Diagnostics has recently decreased by 18.60%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Bluejay Diagnostics does not currently pay a dividend.
Dividend Growth
Bluejay Diagnostics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BJDX.

4.4

News and Social Media Coverage

News Sentiment
Bluejay Diagnostics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Bluejay Diagnostics this week, compared to 0 articles on an average week.
Search Interest
4 people have searched for BJDX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
4 people have added Bluejay Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.
Percentage Held by Insiders
45.30% of the stock of Bluejay Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.21% of the stock of Bluejay Diagnostics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Bluejay Diagnostics are expected to grow in the coming year, from ($0.29) to ($0.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bluejay Diagnostics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bluejay Diagnostics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bluejay Diagnostics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Receive BJDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

BJDX Stock News Headlines

November 13, 2022 | finance.yahoo.com

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) drops to US$14m and insiders who purchased earlier this year lose another US$65k

November 9, 2022 | finance.yahoo.com

Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

October 8, 2022 | fool.com

Investing in Blue Chip Stocks

September 13, 2022 | nasdaq.com

We Think Bluejay Diagnostics (NASDAQ:BJDX) Needs To Drive Business Growth Carefully

August 30, 2022 | finance.yahoo.com

Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 24, 2022 | finance.yahoo.com

Here's Why We're Watching Bluejay Diagnostics' (NASDAQ:BJDX) Cash Burn Situation

August 16, 2022 | finance.yahoo.com

Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

July 27, 2022 | finance.yahoo.com

Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

July 26, 2022 | finance.yahoo.com

Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

July 6, 2022 | finance.yahoo.com

Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

June 9, 2022 | benzinga.com

Why Bluejay Diagnostics Shares Are Surging Higher Today

June 9, 2022 | markets.businessinsider.com

Mid-Day Market Update: Dow Drops 150 Points; Bluejay Diagnostics Shares Jump

May 5, 2022 | finance.yahoo.com

As Bluejay Diagnostics, Inc. (NASDAQ:BJDX) gains 41%, insiders who bought last year may be wishing they had bet higher

April 28, 2022 | uk.investing.com

4 Stocks Under $2 Insiders Are Aggressively Buying

April 20, 2022 | finance.yahoo.com

Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

March 28, 2022 | finance.yahoo.com

Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

March 24, 2022 | seekingalpha.com

Bluejay Diagnostics picks industry veteran for CFO role

March 24, 2022 | marketwatch.com

Bluejay Diagnostics Names Fisher Finance Chief as Kinder Resigns >BJDX

March 24, 2022 | finance.yahoo.com

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

March 17, 2022 | finance.yahoo.com

Companies Like Bluejay Diagnostics (NASDAQ:BJDX) Are In A Position To Invest In Growth

March 12, 2022 | seekingalpha.com

Bluejay Diagnostics GAAP EPS of -$0.09

March 10, 2022 | finance.yahoo.com

Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

February 25, 2022 | investing.com

Bluejay Diagnostics Inc (BJDX)

January 31, 2022 | finance.yahoo.com

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

January 13, 2022 | seekingalpha.com

Bluejay completes 90 subjects in prospective study for COVID-19 test

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BJDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

BJDX Company Calendar

Today: 11/27/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/09/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BJDX
CUSIP: N/A
CIK: 1704287
Web: www.bluejaydx.com
Phone: 978-631-0152
Fax: N/A
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +1,233.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-3,490,000.00
Net Margins: N/A
Pretax Margin: -3,361.77%
Return on Equity: -47.07%
Return on Assets: -43.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.15
Quick Ratio: 9.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.69 per share
Price / Book: 1.09

Miscellaneous

Outstanding Shares: 20,152,000
Free Float: 11,023,000
Market Cap: $15.11 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Indranil Dey (Age 58)
Pres, CEO & Director
Comp: $181.61k

Dr. Jason Cook (Age 40)
Chief Technology Officer
Comp: $308.3k

Mr. Kenneth R. Fisher CPA (Age 42)
Chief Financial Officer

Mr. Edwin Rule
VP of Regulatory, Quality & Compliance

Mr. Kevin Vance (Age 65)
Chief Commercial Officer

Mark W. Feinberg
Chief Medical Advisor

Dr. Mark W. Feinberg M.D.
Chief Medical Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BJDX Stock - Frequently Asked Questions

Should I buy or sell Bluejay Diagnostics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bluejay Diagnostics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BJDX shares.
View BJDX analyst ratings or view top-rated stocks.
What is Bluejay Diagnostics' stock price forecast for 2023?: 1 Wall Street analysts have issued 12-month target prices for Bluejay Diagnostics' stock. Their BJDX share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 1,233.7% from the stock's current price.
View analysts price targets for BJDX or view top-rated stocks among Wall Street analysts.
How have BJDX shares performed in 2022?: Bluejay Diagnostics' stock was trading at $2.56 at the beginning of the year. Since then, BJDX shares have decreased by 70.7% and is now trading at $0.7498.
View the best growth stocks for 2022 here.
When is Bluejay Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our BJDX earnings forecast.

When did Bluejay Diagnostics IPO?: (BJDX) raised $22 million in an IPO on Wednesday, November 10th 2021. The company issued 2,160,000 shares at a price of $10.00 per share.
What is Bluejay Diagnostics' stock symbol?: Bluejay Diagnostics trades on the NASDAQ under the ticker symbol "BJDX."
How do I buy shares of Bluejay Diagnostics?: Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bluejay Diagnostics' stock price today?: One share of BJDX stock can currently be purchased for approximately $0.75.
How much money does Bluejay Diagnostics make?: Bluejay Diagnostics (NASDAQ:BJDX) has a market capitalization of $15.11 million. The company earns $-3,490,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.
How can I contact Bluejay Diagnostics?: The official website for the company is www.bluejaydx.com. The company can be reached via phone at 978-631-0152 or via email at ir@bluejaydx.com.

This page (NASDAQ:BJDX) was last updated on 11/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial